600812 华北制药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.9190.092-12.1070.3071.650
总资产报酬率 ROA (%)0.4800.023-2.9870.0770.454
投入资产回报率 ROIC (%)0.5830.028-3.5930.0910.484

边际利润分析
销售毛利率 (%)30.26431.98133.38035.45635.770
营业利润率 (%)2.9511.546-5.4061.3101.602
息税前利润/营业总收入 (%)7.2726.238-0.1296.8506.647
净利润/营业总收入 (%)1.9370.488-6.4650.3410.909

收益指标分析
经营活动净收益/利润总额(%)73.84248.541-33.27119.75138.671
价值变动净收益/利润总额(%)14.98629.552-7.79028.99614.161
营业外收支净额/利润总额(%)-0.0531.314-0.453-0.8351.356

偿债能力分析
流动比率 (X)0.7830.7810.7240.8931.030
速动比率 (X)0.5610.5270.5210.7250.822
资产负债率 (%)69.56970.07970.65071.85270.518
带息债务/全部投入资本 (%)68.83067.43867.07069.084--
股东权益/带息债务 (%)43.80145.40745.22242.17445.215
股东权益/负债合计 (%)35.52336.19235.35233.97336.290
利息保障倍数 (X)1.6821.335-0.0241.2341.323

营运能力分析
应收账款周转天数 (天)73.26274.02671.82664.0120.000
存货周转天数 (天)129.769134.173126.481130.1090.000